Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Using PU.1 and JDP2 TF expression to predict treatment response and leukemia transformation in MDS

Ciro Rinaldi • 5 May 2023
MDS 2023
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, comments on the role of PU.1 and JDP2 transcription factor (TF) expression in myelodysplastic syndromes (MDS), explaining how this can be used to predict response to treatment and transformation to acute myeloid leukemia (AML). This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ciro Rinaldi

1:12
The potential of targeting mutant calreticulin with antibodies in MPNs
Ciro Rinaldi • 3 Jun 2023
0:58
The potential of CAR-T therapy targeting mutant CALR in myelofibrosis & essential thrombocythemia
Ciro Rinaldi • 3 Jun 2023
1:22
Benefits and drawbacks of the IPSS-M
Ciro Rinaldi • 5 May 2023
1:31
HMA combination strategies in MDS: BLC2, CD47 & TIM-3 inhibitors
Ciro Rinaldi • 5 May 2023

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
2:02
Relapse incidence post-alloSCT with PTCy for AML in CR1
Arnon Nagler • 16 Apr 2024
1:35
Outcomes of alloSCT following blinatumomab in children and young adults with R/R B-ALL
Mattia Algeri • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals